Obstructive Airway Diseases: Role of Lipid Mediators, 1st Edition (Hardback) book cover

Obstructive Airway Diseases

Role of Lipid Mediators, 1st Edition

Edited by Abhijit Ray, Punit Kumar Srivastava

CRC Press

381 pages | 78 B/W Illus.

Purchasing Options:$ = USD
New in Paperback: 9781138374454
pub: 2018-09-18
$71.00
x
Hardback: 9781439851401
pub: 2011-11-28
Currently out of stock
$220.00
x
eBook (VitalSource) : 9780429061660
pub: 2016-04-19
from $35.50


FREE Standard Shipping!

Description

Incidences of inflammatory airway diseases are on the rise across the world. Existing therapeutic options are ineffective, unsafe, and expensive, and severe cases are nonresponsive to conventional therapy. Therefore, it is imperative that research be undertaken to discover new treatment options. Obstructive Airway Diseases: Role of Lipid Mediators discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states.

Topics discussed include:

  • Obstructive airway diseases, etiology, pathophysiology, and existing therapeutic options
  • What constitutes a lipid and how it is broken down to generate biologically active mediators
  • The role of enzymes in the process of lipid mediator synthesis
  • The biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid and the role they play in airway inflammation
  • Products of arachidonic acid metabolism such as leukotrienes, prostaglandins, epieicosatrienoic acid, and oxoeicosatetraenoic acid
  • Proresolution lipid mediators in inflammatory airway disease conditions
  • The role of sphingosine and ceramide in inflammatory airway disease
  • Protein kinases activated by lipid mediators and those that trigger the generation of lipid messengers

The combined input of a panel of international authorities on lipid mediators makes this volume a valuable resource for all those involved in researching, teaching, and studying airway inflammation as well as those involved in drug discovery research.

Punit Srivastava maintains a blog with additional information about the book and his work.

Table of Contents

Obstructive Airway Diseases: Epidemiology, Etiology, and Therapeutic Options

Abhijit Ray

Lipids: Reservoir of Drug Targets

Abhijit Ray and Punit Kumar Srivastava

Phospholipase A2 as a Potential Drug Target for Airway Disorders

Yoshitaka Taketomi and Makoto Murakami

5-Lipoxygenase Pathway: A Validated Route to Drug Discovery

Carlo Pergola and Oliver Werz

Leukotriene Receptor Antagonists and FLAP Inhibitors

Suman Gupta and Sanjay Malhotra

EETs and Oxo-ETE in Airway Diseases

Jun Yang, Hua Dong, and Bruce D. Hammock

The Eosinophil Chemoattractant 5-Oxo-ETE

William S. Powell and Joshua Rokach

Cyclooxygenases and Prostaglandin Receptors

Jitesh P. Iyer, Jitendra Anant Sattigeri, and Sunanda Ghosh Dastidar

Proresolution Mediators of Inflammation in Airway Diseases: Resolvins Pave New Directions

Bruce D. Levy and Charles N. Serhan

Platelet-Activating Factor Antagonist Therapy for Airway Disorders

Punit Kumar Srivastava, Kent E. Pinkerton, and Rishabh Dev

Lysophosphatidic Acid in Airway Inflammation

Yutong Zhao and Viswanathan Natarajan

Sphingolipids in Airway Inflammation

Sameer Sharma and Carole A. Oskeritzian

Protein Kinase C Isozymes and Airway Inflammation

Puneet Chopra, V. Senthil, and Manish Diwan

Prospects for PI3 Kinase Signaling Inhibition in Obstructive Airway Diseases

Kazuhiro Ito and Nicolas Mercado

About the Editors

Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases.

Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.

Subject Categories

BISAC Subject Codes/Headings:
MED008000
MEDICAL / Biochemistry
MED072000
MEDICAL / Pharmacy
MED079000
MEDICAL / Pulmonary & Thoracic Medicine